Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
97%
Infection
45%
Hepatitis C Virus
44%
Liver Cirrhosis
44%
Peginterferon
36%
Hepatitis C
34%
Adverse Event
34%
Boceprevir
33%
Chronic Hepatitis C
31%
Hepatitis C Virus Genotype 1
27%
Interferon
24%
Antivirus Agent
24%
Placebo
18%
Ritonavir
16%
Ombitasvir
14%
Liver Disease
14%
Simeprevir
14%
Hepatic Encephalopathy
14%
Drug
14%
Sofosbuvir
13%
Virus RNA
12%
Clinical Trial
12%
Glecaprevir Plus Pibrentasvir
12%
Paritaprevir
12%
Proteinase Inhibitor
11%
Anemia
11%
Dasabuvir
11%
Daclatasvir
9%
Peginterferon Alpha
9%
Decompensated Liver Cirrhosis
9%
Fibrosis
9%
Relapse
9%
Nonalcoholic Fatty Liver
8%
Telaprevir
8%
Hepatitis B
7%
Fatigue
7%
Nonstructural Protein 5A Inhibitor
7%
Diseases
7%
Complication
7%
Ledipasvir Plus Sofosbuvir
6%
Recurrent Disease
6%
Virus
6%
Glecaprevir
6%
Pibrentasvir
6%
Lamivudine
6%
RNA
5%
Portal Hypertension
5%
Hepatitis B Virus
5%
Rifaximin
5%
Headache
5%
Medicine and Dentistry
Patient
100%
Therapeutic Procedure
59%
Combination Therapy
38%
Ribavirin
27%
Liver Transplantation
24%
Hepatitis C Virus
22%
Inpatient
19%
Liver Cirrhosis
19%
Nonalcoholic Fatty Liver
19%
Hepatitis C
17%
Infection
15%
Thrombocytopenia
15%
Genotype
12%
Interferon
12%
Fibrosis
12%
Liver Disease
11%
Peginterferon
11%
Platelet
11%
Hepatocellular Carcinoma
10%
Hepatic Encephalopathy
10%
Adverse Event
10%
Diseases
10%
Chronic Hepatitis C
9%
Complication
9%
Liver
9%
Chronic Liver Disease
9%
Hepatitis B
8%
Liver Biopsy
8%
Antivirus Agent
8%
Development
7%
Health Care Cost
7%
Boceprevir
7%
Portal Hypertension
7%
Ritonavir
6%
Diagnosis
6%
Transplantation
6%
Recurrent Disease
6%
Hepatitis B Virus
6%
Tioguanine
5%
Decompensated Liver Cirrhosis
5%
Ombitasvir
5%
Prevalence
5%
Hepatitis C Virus Genotype 1
5%
Relapse
5%
Odds Ratio
5%
Dasabuvir
5%
Nursing and Health Professions
Patient
52%
Ribavirin
23%
Sustained Virologic Response
15%
Combination Therapy
14%
Liver Cirrhosis
12%
Infection
11%
Hepatitis C
11%
Chronic Hepatitis C
7%
Inpatient
7%
Treatment Duration
6%
Peginterferon
6%
Boceprevir
5%
Ritonavir
5%
Adverse Event
5%
Ombitasvir
5%
Interferon
5%
